Chronic insomnia in elderly patients significantly affects their health and quality of life (QOL). Nocturia also worsens sleep condition. The aim of this study was to evaluate the improvement effects of quazepam, a long-term acting benzodiazepine, on insomnia and nocturia in elderly patients. Method: Forty-one elderly outpatients (mean age 77.1 ± 5.6 yr) suffering from chronic insomnia while on regular a short-or ultrashort-acting hypnotic treatment were enrolled. We prescribed 7.5-15 mg of quazepam, which was administered regularly by the subjects before bedtime. A questionnaire was used to compared changes in quality of sleep and frequency of nocturia for before treatment and at 2 and 4 weeks after initiation of treatment. QOL was also examined using the 36-item Short Form Health Survey of the Medical Outcomes Study (SF-36). Results: Thirty-seven subjects (90.2%) completed the study. All subscales of the sleep quality questionnaire improved significantly (p<0.001) after 2 weeks, as did the total scores (p<0.001) after 4 weeks. Frequency of nocturia decreased significantly from 3.6 ± 1.7 times to 1.5 ± 0.8 (p<0.001) and 1.2 ± 1.0 times (p<0.001) after 2 and 4 weeks, respectively. Every SF-36 subscale also showed significant improvement after 4 weeks. The total SF-36 scores of the group showing a decrease in the frequency of nocturia (>/= 2 times) improved significantly compared with that with a frequency of < 2 times (p=0.016). Conclusion: Quazepam significantly improves sleep, QOL and nocturia in elderly patients that respond poorly to short-acting or ultra-short-acting hypnotics.
Introduction
Aging often causes serious insomnia, which is accompanied by a decline in the sleep function and disorder of the circadian rhythm in elderly patients 1, 2) . In general, there are four types of sleep disturbance: difficulty in falling sleep, intermittent awakening, early morning awakening and nonrestorative sleep. The latter two types of insomnia are common in elderly patients.
Nocturia sometimes occurs as another aspect of insomnia in elderly patients, even when they have no underlying urological disease. A previous study reported that nocturnal micturition is often associated with increased insomnia; poorer quality of sleep; increased thirst, particularly at night; and increased fatigue in the daytime 3) .
As medical doctors, we must base our selection of hypnotic treatment on the four types of sleep disturbance described above. However, short-acting or ultra-short-acting hypnotics are often prescribed even if the elderly patient with insomnia suffers from early morning awakening and non-restorative sleep.
Quazepam (Doral ® , Mitsubishi Pharma Corporation, Osaka, Japan), a trifluoroethyl benzodiazepine hypnotic with a half-life of 27 to 41 hours, is effective in inducing and maintaining sleep not only in initial and short-term use but also in continued use 4, 5) . At doses of 15 to 30 mg, it is as effective as flurazepam and triazolam at the normal therapeutic doses, and there is minimal rebound of insomnia following withdrawal, unlike rapidly eliminated benzodiazepines such as triazolam. Previous studies have also concluded that low doses of quazepam (7.5 or 15 mg) are effective and safe for older insomniacs 5, 6) .
In this study, we investigated whether Quazepam could improve both insomnia and nocturnal micturition in elderly patients, thereby leading to betterment of their QOL.
Methods

Subjects and study protocol
Elderly outpatients aged 65 years or older complaining of persistent insomnia during regular use of short-acting or ultra-short-acting hypnotics were first selected as subjects.
Inclusion criteria
According to the definitions of insomnia in the Diagnostic and Statistical Manual of Mental Disorders Fourth edition (DSM-IV) 7) and the International Classification of Sleep disorders (ICSD) 8) , the condition of insomnia must occur at least three times a week and persist for more than 4 weeks. The subjects were also required to have at least one of the following two types of insomnia: intermittent awakening and early morning awakening. The patients were also required to be able to understand the contents of the questionnaires and complete them without help.
Exclusion criteria
Individuals with a history of alcohol abuse, epilepsy or psychiatric illness, patients who had symptoms of sleeprelated breathing disorders such as sleep apnea syndrome and symptoms of restless leg syndrome or periodic limb movement disorder and patients with major underlying diseases that were unstable were excluded from the study.
As a result, 41 elderly outpatients (mean age: 77.1 ± 5.6) with psychophysiological insomnia were enrolled in the study. Patient characteristics are shown in Table 1 . Prior to enrollment, all patients received an explanation of the contents of the study. This study was conducted in accordance with the principles embodied in the Helsinki Declaration (as revised in Edinburgh 2000). After obtaining their signed informed consent, the 41 patients were initially given 15 mg of quazepam to take before sleeping. All subjects were also instructed that they could reduce the 15 mg of quazepam to half of the initial administrative dose (7.5 mg), if they felt drowsy or experienced a floating sensation the next day.
Changes in the quality of sleep were examined before and at 2 and 4 weeks after the start of the study using a sleep questionnaire that was almost the same as the one used in the development stage of the drug. The contents of the questionnaire are shown in Table 2 . Each subject was also required to record the frequency of nocturnal micturition every night. In this study, we also used the 36-item Short Form Health Survey of the Medical Outcomes Study (SF-36) before and at 4 weeks after enrollment in the study in order to assess QOL. SF-36 consists of eight subscales that are related to health and functional abilities; physical functioning (PF), physical role (PR), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). It is wellknown to be sensitive to the severity of insomnia and to be a reliable tool for assessment of the impact of insomnia on QOL 9) .
Statistical analysis
The significance level in this study was set at 5%. Each set of data is presented as the mean ± SD. Statistical analyses of the scores for questions in the sleep questionnaire ( Table 3 and Figure 1 ) and frequency of nocturia ( Figure 2 ) compared with those at the time of enrollment were conducted by the Wilcoxon rank order method. Each SF-36 subscore from after 4 weeks of use of quazepam ( Figure 3 ) and those of the group that had a reduced mean frequency of nocturia at least 2 times per night and the one patient whose frequency was less than 2 times ( Figure 4 ) were also compared using the Wilcoxon rank order method. The statistical analyses were carried out using JMP version 5.0.1a (SAS Institute Inc., Cary, NC, USA).
Results
Thirty seven patients (90.2%) completed the entire study period. Four discontinued due to adverse effects even after reducing the dose to half. According to the instructions given prior to the start of the study, subjects were allowed to reduce the administrative dose of quazepam to half if they felt drowsy or they experienced a floating sensation during the daytime. As such, 30 subjects reduced the dose to half. However, the symptoms persisted for several days in 4 sub- jects who subsequently withdrew from the study early. Ultimately, 26 (70.3%) of the 37 study subjects continued to participate in the study at half the dose, while 11 patients continued at the full dose.
Results of the sleep questionnaires (Table 3) (Figure 1)
All subscales of the sleep questionnaire showed significant improvement after 2 (n=28) and 4 weeks (N=37; Table  3 ), and the total scores were also improved significantly at 4 weeks (p<0.001; Figure 1 ). The data for 9 subjects at the 2week stage were omitted from the study analysis because they visited the clinic at 3 weeks rather than 2 weeks. At enrollment, the subjects received 15 mg of the drug for 2 weeks to evaluate each patient's sleep conditions at 2 weeks. However, based on the instructions given before the start of the study, 9 subjects reduced the administrative dose to half (7.5 mg), resulting in an inadequate dose of the drug for 3 weeks.
Change in frequency of nocturnal urination (Figure 2)
Thirty-two patients initially complained of nocturnal urination that became a major reason for the frequent nocturnal awakening. As shown in Figure 2 , the initial mean fre- Changes in the subscales of the SF-36 (Figures 3 and 4) The changes in the SF-36 subscales are shown in Figure  3 . Each of the SF-36 subscales were compared with those obtained from age-matched national standards, which are represented as scores of 50. All subscales of the SF-36 were significantly improved at 4 weeks after initiating administration of quazepam. The SF-36 scores of the group (n=20) showing a reduction in the mean frequency of nocturia of at least 2 times per night improved significantly, particularly in relation to bodily pain (BP), vitality (VT) and mental health (MH); this improvement was not observed in the group (n=12) whose mean frequency decreased to less than 2 times ( Figure 4A, B) .
Adverse effects
Four patients discontinued taking quazepam early in the study, because they felt drowsy and experienced a floating sensation during the daytime, even after reducing the dose to half. No other adverse effects were observed in the other the 37 subjects during the study period. At the end of the study, 30 patients (80.1%) wished to continue taking the drug.
Discussion
In this study, we showed that a 4-week treatment with quazepam significantly improved insomnia and nocturia in elderly patients with psychophysiological insomnia and resulted in a significant improvement of health-related QOL. Few studies have reported the improving effects of quazepam on both QOL and nocturia in older insomniacs who suffer from persistent insomnia, even while regularly using short-acting or ultra-short-acting hypnotics. The mean frequency of nocturia (3.6 ± 1.7 times) was almost twice that during daytime (2.0 ± 0.6 times), suggesting that elderly patients had to void repeatedly once they were aroused at night due to difficulty in falling back to sleep. We also showed that the SF-36 subscores of the group with frequency of nocturia reduced to 2 or more times per night were improved significantly in relation to bodily pain (BP), vitality (VT) and mental health (MH) in particular; however, the group whose frequency improved to less than 2 times per night did not show significant improvements in their SF-36 subscores (Figure 4 ). This finding suggested that the significant improvement in QOL may be attributed partly to the improvement of nocturia by quazepam. When patients complain of nocturnal awakening and early morning awakening, the major patterns of insomnia in elderly patients, use of a long-term acting medication like quazepam rather than a short-acting and ultra-short-acting hypnotics would be beneficial. However, short-acting or ultra-short-acting hypnotics are still being used in clinical practice even though they have little long-term benefit. This is partly due to the fact that there are insufficient anemones for distinguishing patterns of disturbed sleep by medical staff, inadequate explanations are provided to patients and there is concern that hypnotics with long-term efficacy are associated with the risk of tolerance and dependence, next-day sedation and the rebound phenomenon. When choosing hypnotics for older insomniacs, it is important to consider their decline in drug metabolic functions and increased tendency to fall. Hypnotics for the elderly are required to have no effect on muscle relaxation and to trigger no drug dependence, tolerance or rebound insomnia after long-term administration. In addition, a common side effect of benzodiazepine hypnotics is daytime sedation, which is easily recognized and can be managed by dose reduction and/or intermittent use. The rate of daytime sedation by quazepam has previously been reported as 12% 10) . Additionally, a large, open-label large study of 2,813 adult outpatients reported a rate of daytime sedation of only 9 11) . For this reason, we initiated quazepam treatment with a 15 mg dose in the elderly patients in the present study and instructed them to reduce the dose to half if they experienced adverse effects. As a result, 30 subjects (73.2%) reduced the administrative dose to half in accordance with our instructions. Kales reported that daytime sedation could be minimized by intermittent use of a 15 mg dose and normal use of a 7.5 mg dose in the elderly 11) , which is not inconsistent with our results. Ankier also reported that fewer side effects of quazepam, such as daytime sedation, fatigue and lethargy, are observed with a 7.5 mg dose 10) . Therefore, we recommend an initial dose of 7.5 mg of quazepam for geriatric patients.
Final Conclusion
Quazepam significantly improves the sleep conditions, QOL and nocturia of elderly patients who respond poorly to short-acting or ultra-short-acting hypnotics. Although we reported the short-term effects of quazepam in this study, further research is necessary to evaluate the long-term efficacy of this drug in order to secure the most adequate therapeutic management for elderly patients with chronic insomnia.
